

p53 isoforms change p53 paradigm

JC Bourdon*

University of Dundee; College of Medicine; Division of Cancer Research; Dundee Cancer Centre; Dundee, United Kingdom

Keywords: cancer, cdc2-like-kinase, clk, p63, p73, splicing, SRSF1

Although p53 defines cellular responses to cancer treatment it is not clear how p53 can be used to control cell fate outcome. Data demonstrate that so-called p53 does not exist as a single protein, but is in fact a group of p53 protein isoforms whose expression can be manipulated to control the cellular response to treatment.

TP53 is the most frequently mutated gene in human cancers and is thus one of the most studied (72,500 publications, pubmed August 2014). For 25 years it was thought that human *TP53* expressed only one protein, p53. In 2005, we reported that the human *TP53* gene expresses at least 12 p53 proteins (p53 isoforms) as a result of alternative splicing, alternative initiation of translation, and alternative promoter usage.¹ Each p53 isoform contains distinct protein domains. These p53 isoforms were also identified in mouse, zebrafish, and *Drosophila*, suggesting that they play important physiological roles since their expression is conserved through evolution. In normal tissue the human *TP53* gene expresses the following isoforms in a tissue-dependent manner: p53 α (canonical p53), p53 β , p53 γ , Δ 40p53 α , Δ 40p53 β , Δ 40p53 γ , Δ 133p53 α , Δ 133p53 β , Δ 133p53 γ , Δ 160p53 α , Δ 160p53 β , and Δ 160p53 γ . Only p53 α is expressed in every tissue. However, p53 α is never expressed alone; rather, several p53 isoforms are always co-expressed with p53 α in normal human tissue.¹ We and others have analyzed p53 isoform expression in a large panel of cancer cell lines and normal cells derived from diverse tissue origins. None of the normal and cancer cell lines (epithelial or fibroblast) expressed only canonical p53 (p53 α) and p53 α was always co-expressed with several p53 protein isoforms at the cellular level.¹⁻⁷

A large body of evidence has now demonstrated that any changes in cell homeostasis activate a cellular response dependent on p53. Therefore, any anti-cancer drugs or treatments that affect cell homeostasis directly or indirectly activate p53 and trigger a p53-dependent cell response. In other words, the expression of wild-type (WT) *TP53* gene determines whether a cell is going to survive, senesce, proliferate, differentiate, migrate, or die in response to cancer treatment. However, what is the so-called p53 protein? Is p53 only one protein (p53 α) or a group of p53 isoforms? Which protein(s) encoded by the *TP53* gene have the biological and biochemical activities attributed to p53? These questions are of paramount importance because the answers will have a profound impact on the treatment of cancer patients.

In a recently published article entitled "Modulation of p53 β and p53 γ expression by regulating the alternative splicing of *TP53* gene modifies cellular response,"⁸ we investigated whether p53 is a single protein, p53 α , or a group of p53 protein isoforms including p53 α . We determined that endogenous p53 β and p53 γ protein expression can be induced by manipulating the alternative splicing process. To achieve this, we treated a panel of WT *TP53* cell lines with a novel specific inhibitor of Cdc2-like kinases, TG003. Cdc2-like kinases regulate some alternative splicing pre-mRNA processes by

phosphorylating particular splicing factors such as SRSF1 and SRSF3. Importantly, inhibition of Cdc2-like kinases does not abolish all alternative splicing events.

We determined that inhibition of Cdc2-like kinases by TG003 or the knockdown of *SRSF1* promotes the inclusion of *TP53* exons 9 β /9 γ and induces p53 β and p53 γ protein expression. Using siRNA that specifically targeted *TP53* exons 9 β /9 γ with no effect on p53 α expression, we established that endogenous p53 β and p53 γ inhibit cell proliferation by promoting cell death in MCF7 cells grown under standard culture condition. Conversely, by combining TG003 and siRNA targeting specifically *TP53* exons 9 β /9 γ with no effect on p53 α expression, we showed that endogenous p53 β and p53 γ proteins promote proliferation of MCF7 cells upon inhibition of Cdc2-like kinases by TG003. Therefore, p53 β and p53 γ have dual activities, promoting either death or proliferation of WT *TP53* cells depending on the cellular context. Mechanistically, p53 β and p53 γ form stable protein complexes with p53 α on the DNA of p53-responsive promoters such that oligomers composed of p53 β and p53 α and oligomers composed of p53 γ and p53 α regulate expression of different p53-responsive genes. The opposite activities of p53 β and p53 γ isoforms observed in non-treated and TG003-treated cells may reflect the effect of TG003 on both the expression and

© JC Bourdon

*Correspondence to: Jean-Christophe Bourdon; Email: j.bourdon@dundee.ac.uk

Submitted: 08/19/2014; Revised: 08/21/2014; Accepted: 08/22/2014

<http://dx.doi.org/10.4161/23723548.2014.969136>

This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0/>), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted.

post-translational modifications of p53 isoforms, which might alter their oligomerization abilities.

Our data demonstrate that manipulation of endogenous p53 β and p53 γ protein expression using a splicing factor inhibitor and/or siRNA targeting specifically TP53 exons 9 β /9 γ , allows us to trigger different p53-mediated cell responses in a single cell line in a controlled way. This is consistent with previous data; we and others have previously shown that Δ 40p53 α and Δ 133p53 α oligomerize with p53 α and regulate the p53-mediated cell response.⁷

For the past 10 years, we and others have investigated whether p53 is a single protein, p53 α , or a group of p53 isoforms using different animal models (zebrafish,

Drosophila, mouse) and different normal and cancer cell lines derived from distinct human tissues. Irrespective of the cell lines or animal models used, all of the data consistently indicate that the cell fate decision in response to damage or cell signals is defined by the p53 isoforms.⁶⁻¹⁰ Therefore, we can now assert that the protein generally called p53 is NOT a single protein, p53 α , but is in fact an ensemble of different oligomers, each composed of distinct p53 protein isoforms. Each oligomer has a different intrinsic transcriptional activity and promoter specificity. Hence, the p53-mediated cell response would be defined by the sum of the activities of each p53 isoform oligomer. This would explain why manipulation of the cellular composition of p53 isoforms by small molecules

can trigger opposite p53-dependent cell fate outcomes (repair/survival/proliferation or cell death) in the same cell type in response to the same treatment. It is thus imperative to decipher the mechanism of p53-isoform mediated cell fate decisions for efficient clinical application of anticancer drugs including the new p53-targeting drugs such as Nutlin, Prima, and Rita.

In light of the literature discussed here, p53 isoforms offer novel exciting perspectives in basic and translational research that I am convinced will revolutionize cancer treatment, improving patient quality of life and survival.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

References

1. Bourdon JC, Fernandes K, Murray-Zmijewski F, Liu G, Diot A, Xirodimas DP, Saville MK, Lane DP. p53 isoforms can regulate p53 transcriptional activity. *Genes Dev* 2005; 19:2122-37; PMID:16131611; <http://dx.doi.org/10.1101/gad.1339905>
2. Aoubala M, Murray-Zmijewski F, Khoury MP, Fernandes K, Perrier S, Bernard H, Prats AC, Lane DP, Bourdon JC. p53 directly transactivates Delta133p53alpha, regulating cell fate outcome in response to DNA damage. *Cell Death Differ* 2011; 18:248-58; PMID:20689555; <http://dx.doi.org/10.1038/cdd.2010.91>
3. Terrier O, Marcel V, Cartet G, Lane DP, Lina B, Rosa-Calatrava M, Bourdon JC. Influenza A viruses control expression of proviral human p53 isoforms p53beta and Delta133p53alpha. *J Virol* 2012; 86:8452-60; PMID:22647703; <http://dx.doi.org/10.1128/JVI.07143-11>
4. Avery-Kiejda KA, Zhang XD, Adams LJ, Scott RJ, Vojtesek B, Lane DP, Hersey P. Small molecular weight variants of p53 are expressed in human melanoma cells and are induced by the DNA-damaging agent cisplatin. *Clin Cancer Res* 2008; 14:1659-68; PMID:18310316; <http://dx.doi.org/10.1158/1078-0432.CCR-07-1422>
5. Takahashi R, Markovic SN, Scrable HJ. Dominant effects of Delta40p53 on p53 function and melanoma cell fate. *J Invest Dermatol* 2013; 134:791-800; PMID:24037342; <http://dx.doi.org/10.1038/jid.2013.391>
6. Mondal AM, Horikawa I, Pine SR, Fujita K, Morgan KM, Vera E, Mazur SJ, Appella E, Vojtesek B, Blasco MA, Lane DP, Harris CC. p53 isoforms regulate aging- and tumor-associated replicative senescence in T lymphocytes. *J Clin Invest* 2013; 123:5247-57; PMID:24231352; <http://dx.doi.org/10.1172/JCI70355>
7. Surget S, Khoury MP, Bourdon JC. Uncovering the role of p53 splice variants in human malignancy: a clinical perspective. *Onco Targets Ther* 2013; 7:57-68; PMID:24379683
8. Marcel V, Fernandes K, Terrier O, Lane DP, Bourdon JC. Modulation of p53beta and p53gamma expression by regulating the alternative splicing of TP53 gene modifies cellular response. *Cell Death Differ* 2014; 21:1377-87; PMID:24926616; <http://dx.doi.org/10.1038/cdd.2014.73>
9. Dichtel-Danjoy ML, Ma D, Dourlen P, Chatelain G, Napoletano F, Robin M, Corbet M, Levet C, Hafsi H, Hainaut P, Ryoo HD, Bourdon JC, Mollereau B. *Drosophila* p53 isoforms differentially regulate apoptosis and apoptosis-induced proliferation. *Cell Death Differ* 2013; 20:108-16; PMID:22898807; <http://dx.doi.org/10.1038/cdd.2012.100>
10. Ou Z, Yin L, Chang C, Peng J, Chen J. Protein interaction between p53 and Delta113p53 is required for the anti-apoptotic function of Delta113p53. *J Genet Genomics* 2014; 41:53-62; PMID:24576456; <http://dx.doi.org/10.1016/j.jgg.2014.01.001>